Indiana University School of Medicine scientists have identified a promising drug target for Alzheimer's disease. The team found that removing an enzyme from neurons in the brain substantially reduces ...

A new drug, FLAV-27, targets epigenetic changes in Alzheimer’s. In preclinical studies, the drug reduced levels of ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

There’s so much to process after an Alzheimer’s diagnosis. Whether it’s you or a loved one who has this disease, you’re likely working through piles of complicated information, an avalanche of ...

With few treatments available to stop or reverse Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of walking back cognitive decline. Alzheimer’s cases are rising in the ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering ...